EP Patent

EP1536812A2 — Methods for modulating activity of the fxr nuclear receptor

Assigned to City of Hope · Expires 2005-06-08 · 21y expired

What this patent protects

The present invention relates to methods and compositions for modulating genes which are controlled by the FXR nuclear hormone receptor such as Cyp7a, Cyp8b, phospholipid transfer protein, ileal bile acid binding protein, sodium taurocholate cotransporter protein, liver fatty aci…

USPTO Abstract

The present invention relates to methods and compositions for modulating genes which are controlled by the FXR nuclear hormone receptor such as Cyp7a, Cyp8b, phospholipid transfer protein, ileal bile acid binding protein, sodium taurocholate cotransporter protein, liver fatty acid binding protein and bile salt export pump. In a preferred embodiment, the method involves modulation of the gene encoding Cyp7a, the enzyme responsible for a major pathway in the elimination of cholesterol. The invention also relates to methods for screening compounds which bind to and activate or inhibit the FXR nuclear hormone receptor and compounds which activate or inhibit the FXR nuclear hormone receptor.

Drugs covered by this patent

Patent Metadata

Patent number
EP1536812A2
Jurisdiction
EP
Classification
—
Expires
2005-06-08
Drug substance claim
No
Drug product claim
No
Assignee
City of Hope
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.